Login to Your Account



Onconova makes good on its word with second phase III for rigosertib

By Marie Powers
News Editor

Friday, August 14, 2015
Onconova Therapeutics Inc. cheered investors by disclosing the submission of an IND application to the FDA to test the I.V. formulation of rigosertib in a pivotal phase III study in higher-risk myelodysplastic syndromes after the failure of a hypomethylating agent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription